{
    "id": 13857,
    "cites": 7,
    "cited_by": 8,
    "reference": [
        "Acemoglu D, Linn J. Market size in innovation: Theory and evidence from the pharmaceutical industry. Quarterly Journal of Economics 2004;119;3; 1049-1090.",
        "Adams CP, Brantner VV. Estimating the Cost of New Drug Development: Is it really $802 Million? Health Affairs 2006;25;2; 420-428.",
        "Berndt ER, et al. Medicare Part D, prescription drug prices, and treatment quality. Annual Meetings of the American Economic Association, Chicago, IL 2007.",
        "Frank RG, Newhouse JP. Should drug prices be negotiated under Part D of Medicare? And if so, how? Health Affairs 2008;27;1; 33-43.",
        "Kremer M. Pharmaceuticals and the developing world. The Journal of Economic Perspectives 2002;16;4; 67-90.",
        "Lichtenberg FR, Sun SX. The impact of Medicare Part D on prescription drug use by the elderly. Health Affairs 2007;26;6; 1735-1744.",
        "Yin W, et al. The Effect of the Medicare Part D Prescription Benefit on Drug Utilization and Expenditures. Ann Intern Med 2008."
    ]
}